Wells Fargo
BOLD

Wells Fargo’s Audentes Therapeutics, Inc BOLD Stock Holding History

Wells Fargo’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-48,580
Closed -$2.91M – 7282
2019
Q4 		$2.91M Sell
48,580
-34,833
-42% -$1.31M ﹤0.01% 3029
2019
Q3 		$2.34M Buy
83,413
+1,177
+1% +$40.2K ﹤0.01% 3195
2019
Q2 		$3.11M Sell
82,236
-49,669
-38% -$1.91M ﹤0.01% 2970
2019
Q1 		$5.15M Sell
131,905
-3,645
-3% -$105K ﹤0.01% 2525
2018
Q4 		$2.89M Sell
135,550
-294,128
-68% -$7.59M ﹤0.01% 2969
2018
Q3 		$17M Buy
429,678
+31,523
+8% +$1.18M ﹤0.01% 1639
2018
Q2 		$15.2M Buy
398,155
+90,618
+29% +$3.36M ﹤0.01% 1714
2018
Q1 		$9.24M Buy
307,537
+273,511
+804% +$9.26M ﹤0.01% 2079
2017
Q4 		$1.06M Buy
34,026
+19,612
+136% +$538K ﹤0.01% 3891
2017
Q3 		$404K Buy
14,414
+6,667
+86% +$145K ﹤0.01% 4466
2017
Q2 		$148K Hold
7,747
– – ﹤0.01% 4961
2017
Q1 		$132K Buy
7,747
+5,700
+278% +$92.2K ﹤0.01% 5064
2016
Q4 		$37K Buy
+2,047
New +$35.4K ﹤0.01% 5462

Wells Fargo's BOLD Position: Q1 2020 in Review

Wells Fargo sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 48,580 shares — an estimated $2.91M sold.

Wells Fargo first reported a position in BOLD in Q4 2016 and held it in 13 quarters. The position peaked at $17M in Q3 2018. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

  • Wells Fargo reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Wells Fargo sold 48,580 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $2.91M.
  • Wells Fargo first reported a position in Audentes Therapeutics, Inc in Q4 2016 and held it in 13 quarters.
  • Wells Fargo's Audentes Therapeutics, Inc position peaked at $17M in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Wells Fargo's 13F filing for Q1 2020, filed 14 May 2020.